Samsung Bioepis Calls For Improved Education On Biosimilars
White Paper Finds Biosimilars Still Not Clearly Understood By Stakeholders
Renewed efforts are needed to educate healthcare industry stakeholders about biosimilars, Samsung Bioepis has insisted, as the firm published a white paper detailing deficiencies in understanding on the part of patients and healthcare professionals.
